Acalabrutinib for untreated and treated chronic lymphocytic leukaemia – Appraisal Consultation Document

In DRAFT guidance, NICE recommend acalabrutinib for untreated chronic lymphocytic leukaemia in adults, only if they have a 17p deletion or TP53 mutation, and for those who have had 1 previous treatment, only if ibrutinib is their only suitable treatment option.

Source:

National Institute for Health and Care Excellence